Opko Ireland Global Holdings, Limited

Cytochroma Inc.

Opko Renal, LLC

Eirgen Pharma Ltd.

Queen's University at Kingston

The Johns Hopkins University

Proventiv Therapeutics, LLC

Other

Opko IP Holdings Ii, Inc.

Jay A White

Samir P Tabash

P Martin Petkovich

Charles W Bishop

Sammy Asiamah Agudoawu

Glenville Jones

Joel Z Melnick

Eric J Messner

Keith H Crawford

Barbara R Beckett

Stephen A Strugnell

Susan Peers

Gary H Posner

Martin Petkovich

Heather Ramshaw

Byung-Chul Suh

Hong Woon Yang

Kenneth R Crawford

Heung Bae Jeon

Qiang Wang

Mehmet Kahraman

Uttam Saha

Susan H Peers

Steven M Silverman

Sammy A Agudoawu

Bethany Halford

Mark Hatcher

HeungBae Jeon

Jae Kyoo Lee

A stabilized formulation for controlled release of a vitamin D compound is disclosed. The formulation can comprise one or both of 25-hydroxyvitamin Dand 25-hydroxyvitamin Dand a stabilizing compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.

Stabilized modified release vitamin D formulation and method of administering same

Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a salt thereof, and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.

Adjunctive therapy with 25-hydroxyvitamin D and articles therefor

Methods and compositions for reducing serum parathyroid levels in, for example, chronic kidney disease patients are disclosed. In these methods, an effective amount of a modified release formulation of 25-hydroxy vitamin D is orally administered to a patient suffering from secondary hyperparathyroidism to lower the patient's serum intact parathyroid hormone (iPTH) level, while avoiding a surge in serum total 25-hydroxy vitamin D.

Methods and compositions for reducing parathyroid levels

A stabilized formulation for controlled release of a vitamin D compound is disclosed. The formulation comprises one or both of 25-hydroxyvitamin Dand 25-hydroxyvitamin Dand a cellulosic compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.

Stabilized modified release Vitamin D formulation and method of administering same

A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.

Methods for controlled release oral dosage of a vitamin D compound

Method for treating secondary hyperparathyroidism in CKD

Method for controlled release oral dosage of a vitamin D compound

Growing community of inventors

Newmarket, Canada

Jay A White